Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: lupus nephritis + phase iii + preliminary  Related to the article below (Last Update: 5/12/2008)

Statement From the Lupus Foundation of America Regarding the ...
Earthtimes (press release), UK - Apr 29, 2008
The findings are initial results from a Phase II/III study conducted by Genentech, Inc., known as the EXPLORER study. Rituxan is approved by the US Food and ...
Roche Continues Solid Sales Growth in First Quarter of 2008 - Both ...
PharmaLive.com (press release), PA - Apr 17, 2008
Phase III trials in rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis are progressing as planned. A phase III clinical trial ...
Source: Google News

B cell depletion as a novel treatment for systemic lupus erythematosus -
RJ Looney, JH Anolik, D Campbell, RE Felgar, F … - Arthritis Rheum, 2004 - doi.wiley.com
... This was a phase I/II dose-escalation study ... later shows complete resolution of
proliferative nephritis, with mild ... Lupus B cells might be resistant to depletion ...

Systemic lupus erythematosus -
G Ruiz-Irastorza, MA Khamashta, G Castellino, GRV … - The Lancet, 2001 - Elsevier
... Of note, phase III trials with anti-CD40 ligand ... Lupus tends to flare during pregnancy
and the puerperium ... increased prematurity, 80 and active nephritis has been ...

Treatment of severe proliferative lupus nephritis: the current state -
CC Mok, RWS Wong, KN Lai - British Medical Journal, 2003 - ard.bmj.com
... An international phase III trial is underway ... modalities Other potential treatments
for lupus nephritis include the ... 78 They are still in the preliminary stage of ...

Novel therapeutic agents for systemic lupus erythematosus. -
BD Gescuk, JC Davis Jr - Current Opinion in Rheumatology, 2002 - co-rheumatology.com
... Preliminary studies in animal models of SLE demonstrated that ... A phase III trial is
underway to determine efficacy of LJP 394 in lupus nephritis patients with ...

[PDF] Management of lupus nephritis: an update -
FA Houssiau - J Am Soc Nephrol, 2004 - uphs.upenn.edu
... In a phase I/II trial, 16 SLE patients were given RTX (one ... ciety (RPS) (93) and may
be associated with class III (focal) or ... Management of Lupus Nephritis 2699 ...
-

Hematopoietic stem cell transplantation for severe and refractory lupus -
AE Traynor, WG Barr, RM Rosa, J Rodriguez, Y Oyama … - Arthritis & Rheumatism, 2002 - doi.wiley.com
... A phase III randomized trial is warranted to determine ... World Health Organization
class III or class ... K, Phillips EA, for the Lupus Nephritis Collaborative Study ...

Flaxseed in Lupus Nephritis: A Two-Year Nonplacebo-Controlled Crossover Study -
WF Clark, C Kortas, AP Heidenheim, J Garland, E … - Journal of the American College of Nutrition, 2001 - Am Coll Nutrition
... These preliminary findings led to this current two-year ... for use in patients with
lupus nephritis by the ... a three month washout followed by Phase III with a ...

Novel approaches in the treatment of lupus nephritis -
GG Illei, L Czirjak - Expert Opin Investig Drugs, 2001 - Expert Opinion
... Further Phase III studies would be necessary to evaluate the real ... Decreasing IL-10
levels in lupus-prone mice by ... delayed the onset of nephritis and increased ...

Newer Drugs for the Treatment of Lupus Nephritis. -
DG Kuiper-Geertsma, RHWM Derksen - Drugs, 2003 - drugs.adisonline.com
... levels at 16 and 24 weeks, respectively.[80] A phase II/III trial was ... place in the
therapeutic armamentarium of clinicians treating lupus nephritis has been ...

… Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis -
GG Illei, HA Austin III, M Crane, L Collins, MF … - Annals of Internal Medicine, 2001 - annals.highwire.org
... Illei, MD ; Howard A. Austin, III, MD ; Marianna ... regulation in the follow-up phase
may have ... effective for treatment of proliferative lupus nephritis and should ...

Source: Google Scholar

Preliminary Results For Phase III Study Evaluating CellCept In Lupus Nephritis
Aspreva Pharmaceuticals Corporation and Roche today released preliminary results for a clinical phase III trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.

Although response rates were similar in both arms, the trial did not meet its primary objective of demonstrating that MMF was superior to IVC in inducing treatment response in this disease. The results relate to the induction phase of this study, which was designed to measure treatment response in patients after 24 weeks of induction therapy with 185 patients in the MMF arm and 185 in the IVC arm.
The results indicate similar treatment responses were observed, with 56.2% in the MMF arm and 53% in the IVC arm. Additional analyses are ongoing to determine the potential for regulatory submission, and Aspreva plans to present the final results at an appropriate scientific forum in the future.

Based on preliminary analysis, it appears that, in general, the adverse events experienced by patients in both arms of the study are consistent with those observed in lupus nephritis patients receiving immunosuppressive therapy. Overall incidence of adverse events was comparable in both treatment arms.

About Lupus Nephritis

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease that causes the body to attack its own tissues and joints. Lupus nephritis, considered life threatening but rare, is the most serious manifestation of the disease, which, if left untreated, can lead to kidney failure, requiring dialysis and potentially death. It is a complicated disease as patients typically fluctuate between periods of intense disease activity when the patient's own immune system is actively attacking and causing damage in their kidney, interspersed with periods of remission. Clinicians estimate that one third to one half of lupus patients have lupus nephritis. There has been no new approved treatment for SLE or lupus nephritis in the United States in over forty years. Current treatments involve the off-label use of existing cancer drugs such as cyclophosphamide, steroids, and other immunosuppressant drugs such as azathioprine.
About CellCept

CellCept is Roche's leading immunosuppressant or "anti-rejection" drug. It is used in combination with other immunosuppressive drugs (cyclosporine and corticosteroids) for the prevention of rejection in patients receiving heart, kidney and liver transplants. CellCept was first approved for use in combination therapy for the prevention of acute organ rejection in kidney transplantation in 1995 and has since been approved worldwide for prevention of organ rejection in adult kidney, heart and liver transplantation. This therapeutic success in the prevention of organ rejection in adult kidney, heart and liver transplantation represents 11 years of clinical experience and patient benefits, including reduced toxicities and prolonged graft and patient survival. In July 2003, Aspreva signed a collaboration agreement with Roche for the exclusive worldwide rights (excluding Japan) to develop and, upon regulatory approval, commercialise CellCept for all autoimmune disease applications. It is important to note that CellCept has not been approved by the FDA for the treatment of any autoimmune disease.

About Aspreva Pharmaceuticals

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercialising evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol "ASPV" and on the Toronto Stock Exchange under the trading symbol "ASV". Learn more at http://www.aspreva.com.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at http://www.roche.com.
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.